Bank Of Montreal Vir Biotechnology, Inc. Transaction History

Bank Of Montreal

$202 Billion
Q4 2024

A detailed history of Bank Of Montreal transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Bank Of Montreal holds 10,036 shares of VIR stock, worth $81,391. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,036

Previous 11,575 13.3%

Holding current value

$81,391

Previous $86,000 15.12%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$6.74 - $10.17 $10,372 - $15,651	-1,539 Reduced 13.3%	10,036 $73,000
Q3 2024 Nov 13, 2024	SELL	$7.26 - $10.7 $19,957 - $29,414	-2,749 Reduced 19.19%	11,575 $86,000
Q2 2024 Aug 14, 2024	SELL	$7.63 - $12.66 $50,060 - $83,062	-6,561 Reduced 31.41%	14,324 $127,000
Q1 2024 May 13, 2024	BUY	$8.6 - $11.9 $53,431 - $73,934	6,213 Added 42.35%	20,885 $211,000
Q4 2023 Feb 08, 2024	SELL	$7.76 - $10.29 $5,579 - $7,398	-719 Reduced 4.67%	14,672 $147,000
Q3 2023 Nov 01, 2023	BUY	$9.14 - $24.62 $35,115 - $94,590	3,842 Added 33.27%	15,391 $144,000
Q2 2023 Aug 02, 2023	BUY	$23.2 - $27.29 $31,691 - $37,278	1,366 Added 13.41%	11,549 $283,000
Q1 2023 Jun 13, 2024	SELL	$22.26 - $30.85 $183,555 - $254,389	-8,246 Reduced 39.48%	12,639 $294,000
Q4 2022 Feb 01, 2023	SELL	$19.96 - $28.22 $1,796 - $2,539	-90 Reduced 0.88%	10,183 $257,000
Q3 2022 Nov 10, 2022	BUY	$18.26 - $31.1 $38,930 - $66,305	2,132 Added 26.19%	10,273 $308,000
Q2 2022 Aug 11, 2022	BUY	$19.08 - $26.7 $155,330 - $217,364	8,141 New	8,141 $217,000
Q4 2021 Feb 11, 2022	SELL	$30.97 - $54.03 $6.38 Million - $11.1 Million	-205,896 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$34.9 - $54.54 $7.19 Million - $11.2 Million	205,896 New	205,896 $8.93 Million

Others Institutions Holding VIR

# of Institutions

232

Shares Held

90.1M

Call Options Held

1.28M

Put Options Held

235K

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.08B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account